The estimated Net Worth of J Erik Fyrwald is at least 18.2 百万$ dollars as of 11 March 2020. Mr. Fyrwald owns over 12,500 units of Lilly(Eli) & Co stock worth over 17,898,418$ and over the last 19 years he sold LLY stock worth over 0$. In addition, he makes 325,000$ as Independent Director at Lilly(Eli) & Co.
Sign up
Mr. Fyrwald LLY stock SEC Form 4 insiders trading
J has made over 4 trades of the Lilly(Eli) & Co stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 12,500 units of LLY stock worth 497,750$ on 11 March 2020.
The largest trade he's ever made was buying 20,000 units of Lilly(Eli) & Co stock on 23 June 2015 worth over 440,000$. On average, J trades about 395 units every 15 days since 2005. As of 11 March 2020 he still owns at least 19,436 units of Lilly(Eli) & Co stock.
You can see the complete history of Mr. Fyrwald stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
J. Erik Fyrwald biography
J. Erik Fyrwald serves as Independent Director of the Company. He is President and Chief Executive Officer, Univar, Inc. He joined Univar Inc., a distributor of industrial and specialty chemicals and provider of related services, in May 2012 as its president and chief executive officer. In 2008, following a 27-year career at E.I. duPont de Nemours and Company (DuPont), he joined Nalco Company, serving as chairman and chief executive officer until 2011, when Nalco merged with Ecolab Inc. Following the merger, Mr. Fyrwald served as president of Ecolab. From 2003 to 2008, Mr. Fyrwald served as group vice president of the agriculture and nutrition division at DuPont. From 2000 until 2003, he was vice president and general manager of DuPont's nutrition and health business. At DuPont, he held a broad variety of assignments in a number of divisions covering many industries. He has worked in several locations throughout North America and Asia. Mr. Fyrwald serves as a director of the Society of Chemical Industry, Amsted Industries, and the Chicago Public Education Fund, and he is a trustee of the Field Museum of Chicago.
What is the salary of J Fyrwald?
As the Independent Director of Lilly(Eli) & Co, the total compensation of J Fyrwald at Lilly(Eli) & Co is 325,000$. There are 7 executives at Lilly(Eli) & Co getting paid more, with David Ricks having the highest compensation of 21,283,200$.
How old is J Fyrwald?
J Fyrwald is 60, he's been the Independent Director of Lilly(Eli) & Co since 2005. There are 7 older and 24 younger executives at Lilly(Eli) & Co. The oldest executive at Lilly(Eli) & Co is Kathi Seifert, 71, who is the Independent Director.
Insiders trading at Lilly(Eli) & Co
Over the last 20 years, insiders at Lilly(Eli) & Co have traded over 29,994,829,903$ worth of Lilly(Eli) & Co stock and bought 73,808 units worth 5,778,435$ . The most active insiders traders include Endowment Inc Lilly、R David Hoover、Lorenzo Tallarigo. On average, Lilly(Eli) & Co executives and independent directors trade stock every 7 days with the average trade being worth of 55,447,708$. The most recent stock trade was executed by Endowment Inc Lilly on 3 September 2024, trading 24,084 units of LLY stock currently worth 23,281,762$.
What does Lilly(Eli) & Co do?
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.
What does Lilly(Eli) & Co's logo look like?
Complete history of Mr. Fyrwald stock trades at Bunge Global SA、Ecolab、Lilly(Eli) & Co、International Flavors & Fragrances、Univar Solutions Inc
Lilly(Eli) & Co executives and stock owners
Lilly(Eli) & Co executives and other stock owners filed with the SEC include:
-
David Ricks,
Chairman of the Board, President, Chief Executive Officer -
Joshua Smiley,
Chief Financial Officer, Senior Vice President -
Daniel Skovronsky,
Senior Vice President, Chief Scientific Officer and President, Lilly Research Laboratories -
David A. Ricks,
Chairman, CEO & Pres -
Anat Hakim J.D.,
Sr. VP, Gen. Counsel & Sec. -
Jackson Tai,
Independent Director -
Juan Luciano,
Lead Independent Director -
J. Erik Fyrwald,
Independent Director -
Karen Walker,
Independent Director -
William Kaelin,
Independent Director -
Michael Eskew,
Independent Director -
Jamere Jackson,
Independent Director -
Katherine Baicker,
Independent Director -
Raul Alvarez,
Independent Director -
Kathi Seifert,
Independent Director -
Marschall Runge,
Independent Director -
Carolyn Bertozzi,
Independent Director -
Alfonso Zulueta,
Senior Vice President, President - Lilly International -
Ilya Yuffa,
Senior Vice President and President of Lilly Bio-Medicines -
Anne White,
Senior Vice President, President - Lilly Oncology -
Leigh Pusey,
Senior Vice President - Corporate Affairs and Communications -
Myles O'Neill,
Senior Vice President and President - Manufacturing Operations -
Johna Norton,
Senior Vice President - Global Quality -
Michael Mason,
Senior Vice President and President, Lilly Diabetes -
Patrik Jonsson,
Senior Vice President, President of Lilly USA , and Chief Customer Officer -
Stephen Fry,
Senior Vice President - Human Resources and Diversity -
Anat Hakim,
Senior Vice President, General Counsel -
Melissa Barnes,
Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer -
Aarti Shah,
Senior Vice President - Chief Information and Digital Officer -
Leigh Ann Pusey,
Sr. VP of Corp. Affairs & Communications -
Alonzo Weems,
Sr. VP and Chief Ethics & Compliance Officer -
Diogo Rau,
Sr. VP & Chief Information and Digital Officer -
Kevin Hern,
VP of Investor Relations -
Martin Bott MIBS,
VP of Fin. & Special Projects -
Donald A. Zakrowski,
Chief Accounting Officer & VP of Fin. -
Jacob S. Van Naarden,
Chief Operating Officer of Loxo Oncology -
Anat Ashkenazi,
Sr. VP & CFO -
Eric Dozier,
EVP, HR & Diversity -
Endowment Inc Lilly,
-
Christi Shaw,
SVP and Pres., Lilly Bio-Meds -
Fionnuala M Walsh,
SVP, Global Quality -
Jan M Lundberg,
EVP,Science&Tech and Pres. LRL -
Maria A Crowe,
President, Mfg. Operations -
Ralph Alvarez,
Director -
Michael J Harrington,
Senior VP and General Counsel -
Jeffrey N Simmons,
SVP&Pres.,Elanco Animal Health -
Susan Mahony,
SVP, HR & Diversity -
Barton R Peterson,
Sr. VP, Corp. Affairs & Comm. -
Derica W Rice,
Sr. Vice President and CFO -
Enrique A Conterno,
Sr. VP & Pres., Lilly Diabetes -
Naarden Jacob Van,
EVP & Pres., Loxo@Lilly -
Donald A Zakrowski,
SVP, Finance, & CAO -
Karen N Horn,
Director -
John C Lechleiter,
President and COO -
Alonzo Weems,
EVP, ERM & CECO -
R David Hoover,
Director -
Franklyn G Prendergast,
Director -
Ellen R Marram,
Director -
Douglas R Oberhelman,
Director -
Anne Nobles,
Chief Eth/Cmpl Ofcr & SVP, ERM -
Bryce D. Carmine,
EVP and Pres, Lilly Bio-Meds -
Robert A Armitage,
Sr. VP and General Counsel -
Steven M Paul,
EVP, Science and Technology -
Frank M Deane,
President, Manufacturing -
J Michael Cook,
Director -
Alfred G Gilman,
Director -
Martin S Feldstein,
Director -
Sidney Taurel,
Chairman, President and CEO -
Alex M Ii Azar,
Sr. VP, Corp. Affairs & Comm. -
Gino Santini,
Sr.VP, Corp. Strategy & Policy -
Deirdre P Connelly,
President, Lilly USA -
Anthony John Murphy,
Senior VP, Human Resources -
Jacques Tapiero,
SVP&Pres., Emerging Markets -
Winfried F W Sir Bischoff,
Director -
Arnold C Hanish,
Chief Accounting Officer -
Lorenzo Tallarigo,
President, Internat'l Opers. -
George M C Fisher,
Director -
Scott A Canute,
President, Mfg. Operations -
Charles E Golden,
Exec. Vice President and CFO -
Kimberly H Johnson,
Director -
Anat Ashkenazi,
EVP & CFO -
Diogo Rau,
EVP & CIDO -
Edgardo Hernandez,
EVP & Pres., Mfg. Operations -
Gabrielle Sulzberger,
Director -
Mary Lynne Hedley,
Director -
Melissa Seymour,
EVP, Global Quality